Last updated on March 2019

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer


Brief description of study

The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone).

Clinical Study Identifier: NCT03148795

Contact Investigators or Research Sites near you

Start Over

Pfizer Pfizer CT.gov Call Center

Icon Cancer Care Chermside
Chermside, Australia
  Connect »

Pfizer Pfizer CT.gov Call Center

Icon Cancer Care South Brisbane
South Brisbane, Australia
6.32miles
  Connect »

Pfizer Pfizer CT.gov Call Center

Ion Cancer Care
South Brisbane, Australia
6.32miles
  Connect »

Pfizer Pfizer CT.gov Call Center

Icon Cancer Care Wesley
Auchenflower, Australia
6.61miles
  Connect »

Pfizer Pfizer CT.gov Call Center

River City Pharmacy
Auchenflower, Australia
6.61miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.